Jeevan Scientific Technology Ltd Company Summary

Jeevan Scientific Technology Limited, erstwhile known as Jeevan Softech Limited was incorporated on 2nd February, 1999 to carry on the business Clinical research, Data Management Services. The Company was promoted by Krishna Kishore Kuchipudi and K Vanaja. The Company is an Independent Clinical Contract Research Organization offering reliable, cost effective and technology-driven clinical research solutions to various clients across the globe.

The name of the Company was changed from Jeevan Softech Limited to Jeevan Scientific Technology Limited in April, 2012.The Company started with an overall focus on Products Development, International and Domestic markets and Training segment. During the year 2000-01, company had developed and released products for Edible Oil Industry,Engineering Industry,Hospital Management.The company is the member of STPI under 100% Export oriented unit Registration scheme and also achieved Software Exports during 2000-01,to USA based organisation C.S.Consultants Inc.The company entered into an agreement with the University of Madras as a study centre for Hyderabad to provide MCA, M. Sc., MBA through distance education mode by the Jeevan School of Computer Sciences, a division of Jeevan Softech Limited.In 2011, the Company started Medical Writing Services.

It opened Jeevan Scientific New Corporate and Bioanalytical Lab facility in December, 2014. The Clinical Pharmacology Unit with 132 bed capacity opened in Balanagar, Hyderabad in October, 2016. Thereafter, it completed BA/BE studies on 08 June, 2017.

In FY 2018-19, the Company acquired nearly 10 LC-MS/MS systems which got launched to accommodate possible work. Thereafter, it started offering clinical research services like Bioavailability/Bioequivalence studies and Phase I to Phase IV services to pharmaceutical and biotechnology industries. In 2021-22, Company launched its first UK MHRA inspection of both facilities.

Further, Company invested in 20,00,000 equity shares of Rs 10 each of Nayas Laboratories Private Limited, constituting 88.9% of the post paid up equity share capital of Nayas Laboratories Private Limited, making it a subsidiary of the Company in 2022-23.